Deadly crash near Yellowstone Park: Harris County man at fault, Idaho police say
The Brief
Seven people died following a car collision near Yellowstone Park in early May.
A 25-year-old from Humble, Texas, was identified as one of the people who died.
Idaho police say the man's blood alcohol content was more than twice the legal limit at the time of the crash.
FREMONT COUNTY, Idaho - Idaho State Police have released more information on a deadly car crash near Yellowstone Park that involved a man from Harris County.
What we know
The crash happened on May 1 on a highway about 16 miles west of Yellowstone National Park, according to the Associated Press.
Officials say 25-year-old Isaih Moreno of Humble, Texas, was driving a pickup truck that collided with a van that was taking tourists to Yellowstone.
Police say the Dodge Ram pickup was driving west when it crossed the center line and crashed into the van that was going east.
Moreno was among seven people who were killed in the crash. Idaho police say he was driving the pickup truck.
In an update on Friday, police said the driver at fault had a blood alcohol content of 0.20, which is more than twice the legal limit of 0.08.
RELATED: Harris County man identified as victim in crash near Yellowstone Park; six others killed
What they're saying
According to Idaho State Police, alcohol-related crashes are one of the leading causes of traffic deaths in the state.
The crash near Yellowstone happened as Idaho entered the 100 Deadliest Days, which police say is the period between Memorial Day and Labor Day when traffic deaths tend to rise.
In the Friday update, Idaho State Police and the Idaho Transportation Department said they're urging drivers to make "safe, sober choices."
"This tragedy should be a wake-up call," ISP Captain Chris Weadick said. "No one plans to cause a crash or take a life when they get behind the wheel, but choices have consequences. Impaired driving isn't just illegal — it's deadly. If you see someone unfit to drive, speak up. Lives depend on it."
The Source
Information in this article comes from the Idaho State Police, the Associated Press, and previous FOX 26 reporting.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
URGN STOCK: Suffer Losses on UroGen Pharma Ltd.? BFA Law Notifies Investors of Imminent July 28 Securities Class Action Deadline (NASDAQ:URGN)
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in UroGen you are encouraged to obtain additional information by visiting Investors have until July 28, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased UroGen securities. The case is pending in the U.S. District Court for the District of New Jersey and is captioned: Cockrell v. UroGen Pharma Ltd., et al., No. 3:25-cv-06088. Why was UroGen Sued for Securities Fraud? UroGen develops treatments for specialty cancers. The Company's lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer. One of the Phase 3 trials for UGN-102 is named ENVISION. As alleged, UroGen stated that the ENVISION trial met its primary endpoint and that UroGen had reached 'agreement with the FDA' that the ENVISION trial would support an NDA submission. In truth, the FDA had previously expressed significant concerns to UroGen regarding the ENVISION trial, which lacked a concurrent control arm. The Stock Declines as the Truth is Revealed On May 16, 2025, the FDA published a briefing document stating that it doubted whether the submitted data was sufficient to conclude that UGN-102 was effective. FDA stated that because 'ENVISION lacked a concurrent control arm,' the primary endpoints were 'difficult to interpret' and that UroGen 'chose not to conduct a randomized trial with a design and endpoints that the FDA considered appropriate.' On this news, the price of UroGen stock declined $2.54 per share, or nearly 26%, from a closing price of $9.85 per share on May 15, 2025, to $7.31 per share on May 16, 2025. Then, on May 21, 2025, the Oncologic Drugs Advisory Committee voted against approving the UGN-102 NDA, finding that the overall benefit-risk profile of UGN-102 was not favorable in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer. On this news, the price of UroGen stock declined $3.37 per share, or nearly 45%, from a closing price of $7.54 per share on May 20, 2025, to $4.17 per share on May 21, 2025. Click here if you suffered losses: What Can You Do? If you invested in UroGen you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz [email protected] 212-789-3619 Why Bleichmar Fonti & Auld LLP? Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.
Associated Press
an hour ago
- Associated Press
Book Review: A diary sends a woman on a quest to solve the cold case of 6 missing Black girls
At age 13, Sydney Singleton discovered an old photograph tucked away in a drawer in her paternal grandmother's guest room. It was a portrait of a Black girl just entering her teen years — a girl who looked a lot like Sydney. Next morning, Sydney asked her grandmother about it. The woman, her voice 'firm as the oak tree on her front lawn,' would say only this: 'We don't talk about Carol.' Two decades later, Sydney, now a married woman in her mid-30s, flies from her Los Angeles home to Raleigh, North Carolina, to help prepare her late grandmother's home for sale. There, she and her younger sister, Sasha, find the photograph again. They also find Carol's diary concealed above a ceiling panel in the guest room closet. So begins Kristen L. Berry's fine debut novel, 'We Don't Talk About Carol,' a tale that is at once an exploration of family secrets, a 60-year-old cold case investigation and a damning indictment of the short shrift missing Black girls get from both the authorities and the media. Carol, it turns out, was Sydney's late father's older sister. Her diary, written when she was about 16, reveals that she had an older boyfriend, aspired to be a singer and planned to run away to Detroit to try out with Motown. Carol's family, believing the child had run off, never filed a missing person report. So Sydney, a former investigative reporter, feels compelled to discover what happened to the aunt she never knew existed. Before long, she learns that Carol was one of six Black teenage girls who disappeared from the same Raleigh neighborhood 60 years ago and were dismissed as runaways by the police. Sydney's investigation promptly turns into a quest to learn the fates of all of them. Along the way, she finds allies among the missing girls' families, cold crime podcast enthusiasts and a Raleigh homicide detective. The result is a well-written, emotionally wrenching tale about the generational consequences of evil, the meaning of family and what a single dedicated woman can accomplish. After the diary is discovered, the plot unfolds slowly as the author introduces us to Sydney's suicidal father, her emotionally distant mother and her struggle to conceive a baby with her loving husband, Malik. The pace could lead some readers to abandon the book, but don't. The tale soon picks up speed, taking readers through propulsive a series of revelations, the most sunning of which involves Carol's fate. ___ Bruce DeSilva, winner of the Mystery Writers of America's Edgar Award, is the author of the Mulligan crime novels including 'The Dread Line.' ___ AP book reviews:
News24
an hour ago
- News24
Emotions run high as D-Day approaches for Nada-Jane's alleged killer
Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, and empowerment. You can only trial once. Start your FREE trial now
